Your Article Summary
See Latest ArticlesNitazoxanide and Probiotics for the Treatment of Recurrent Clostridium difficile Infection in a Peritoneal Dialysis Patient
Southern Medical Journal, 07/02/09
Yangco BG et al. - A 58-year-old woman was admitted with hypotension, nausea and vomiting attributed to metronidazole therapy for CDI, her third CDI treatment regimen in 3 months. During her admission, the patient developed CDI and was started on a 6-week regimen of nitazoxanide and probiotics to assist in re-establishing the colonic flora. The regimen was well tolerated and the patient remained disease free at follow up, four months later.
Related Articles
The Anti-Hepatitis C Agent Nitazoxanide Induces Phosphorylation of Eukaryotic Initiation Factor 2alpha Via Protein Kinase Activated by Double-Stranded RNA Activation
Gastroenterology, 10/29/09
Relevance Score: 80%
Today in GI Infectious Disease...keeping you current
Receive free subspecialty "5-minute updates" via email
Use of colony-based bacterial strain typing for tracking the fate of Lactobacillus strains during human consumption
BMC Microbiology, 12/09/09
Acute pancreatitis in pregnancy
World Journal of Gastroenterology, 12/09/09
Admission Volume Determines Outcome for Patients With Acute Pancreatitis
Gastroenterology, 12/09/09
Today in Pharmacology/kinetics...keeping you current
Receive free subspecialty "5-minute updates" via email
Update on the role of modified release mesalamine in the management of ulcerative colitis and Crohn's disease
Clinical and Experimental Gastroenterology, 12/09/09
Delayed-Release Oral Mesalamine 4.8 g/day (800-mg Tablet) Is Effective for Patients With Moderately Active Ulcerative Colitis
Gastroenterology, 12/09/09
Effect of HCV RNA Suppression During Peginterferon Alfa-2a Maintenance Therapy on Clinical Outcomes in the HALT-C Trial
Gastroenterology, 12/09/09